|
pubmed:abstractText |
Bendamustine is an anti-neoplastic agent approved by the FDA in 2008 for use as monotherapy or in combination with other agents to treat chronic lymphocytic leukemia (CLL) and progressed indolent B-cell non-Hodgkin lymphoma (NHL). In clinical trials and post-marketing safety reports administration of bendamustine with drugs that have known adverse reactions (i.e., allopurinol, rituximab) has been associated with rash, toxic skin reactions, and bullous exanthems. Here, we describe a patient with NHL who developed a severe cutaneous reaction associated with the administration of bendamustine. The severity of this drug eruption identifies an important adverse reaction with this drug and a potential cause for patient morbidity.
|
|
pubmed:affiliation |
Division of Dermatology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
|
